Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSPNASDAQ:MXCTNASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$39.30+14.7%$41.14$30.04▼$67.88$3.37B1.851.62 million shs3.65 million shsMXCTMaxCyte$2.58+10.3%$3.34$2.21▼$5.26$274.29M1.39526,412 shs445,053 shsVRTXVertex Pharmaceuticals$484.22+1.8%$484.84$377.85▼$519.88$124.34B0.51.33 million shs1.57 million shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics+14.71%+20.37%-9.63%-0.98%-36.35%MXCTMaxCyte+10.26%+5.31%-18.87%-41.36%-36.92%VRTXVertex Pharmaceuticals+1.84%+2.02%-2.26%+18.23%+21.79%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRSPCRISPR Therapeutics2.8102 of 5 stars4.21.00.00.02.23.30.6MXCTMaxCyte2.2129 of 5 stars3.52.00.00.02.22.50.6VRTXVertex Pharmaceuticals3.7445 of 5 stars2.33.00.03.33.52.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.48Hold$73.1186.02% UpsideMXCTMaxCyte 3.00Buy$8.67235.92% UpsideVRTXVertex Pharmaceuticals 2.64Moderate Buy$512.415.82% UpsideCurrent Analyst Ratings BreakdownLatest MXCT, VRTX, and CRSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$84.00 ➝ $84.004/1/2025VRTXVertex PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$408.00 ➝ $420.003/31/2025VRTXVertex PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$555.00 ➝ $567.003/12/2025MXCTMaxCyteBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$6.003/12/2025MXCTMaxCyteStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $9.002/20/2025VRTXVertex PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$407.00 ➝ $408.002/19/2025CRSPCRISPR TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral2/18/2025CRSPCRISPR TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$89.00 ➝ $82.002/14/2025CRSPCRISPR TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderweight ➝ Underweight$30.00 ➝ $32.002/14/2025CRSPCRISPR TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeIn-Line ➝ Outperform$60.00 ➝ $99.002/13/2025CRSPCRISPR TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$66.00 ➝ $57.00(Data available from 4/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$35M96.31N/AN/A$22.52 per share1.75MXCTMaxCyte$38.63M7.10N/AN/A$2.23 per share1.16VRTXVertex Pharmaceuticals$11.02B11.28N/AN/A$63.90 per share7.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$366.25M-$4.37N/AN/AN/A-981.54%-18.46%-15.79%5/6/2025 (Estimated)MXCTMaxCyte-$37.92M-$0.39N/AN/AN/A-78.36%-16.00%-13.93%5/7/2025 (Estimated)VRTXVertex Pharmaceuticals-$535.60M-$2.20N/A27.652.11-4.86%-2.02%-1.49%5/5/2025 (Estimated)Latest MXCT, VRTX, and CRSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025MXCTMaxCyte-$0.10N/AN/AN/A$9.05 millionN/A5/5/2025Q1 2025VRTXVertex Pharmaceuticals$4.24N/AN/AN/A$2.85 billionN/A2/11/2025Q4 2024CRSPCRISPR Therapeutics-$1.15-$0.44+$0.71-$0.44N/AN/A2/10/2025Q4 2024VRTXVertex Pharmaceuticals$3.99$3.54-$0.45$3.50$2.78 billionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AMXCTMaxCyteN/AN/AN/AN/AN/AVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR TherapeuticsN/A22.0722.07MXCTMaxCyteN/A9.819.22VRTXVertex Pharmaceuticals0.012.692.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%MXCTMaxCyte68.81%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.10%MXCTMaxCyte3.00%VRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics47385.77 million82.26 millionOptionableMXCTMaxCyte80106.31 million102.67 millionOptionableVRTXVertex Pharmaceuticals6,100256.79 million256.28 millionOptionableMXCT, VRTX, and CRSP HeadlinesRecent News About These CompaniesAPG Asset Management US Inc. Sells 666 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 11 at 7:28 AM | marketbeat.comVertex Pharmaceuticals Inc (VRTX) Celebrates Prestigious Award for Cystic Fibrosis Research | ...April 11 at 7:08 AM | gurufocus.comMartingale Asset Management L P Lowers Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 11 at 6:55 AM | marketbeat.comAzimuth Capital Investment Management LLC Has $8.92 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 11 at 6:54 AM | marketbeat.comVertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic FibrosisApril 11 at 5:30 AM | businesswire.comArrowstreet Capital Limited Partnership Takes $3.73 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 11 at 4:03 AM | marketbeat.comVertex Pharmaceuticals (VRTX) Surged on Increased Demand for its Cystic Fibrosis (CF) FranchiseApril 10 at 9:39 AM | insidermonkey.comAPG Asset Management N.V. Raises Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 10 at 8:32 AM | marketbeat.comRenaissance Technologies LLC Reduces Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 10 at 7:10 AM | marketbeat.comShelton Capital Management Buys 647 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 10 at 6:52 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Position Lessened by Twin Capital Management Inc.April 10 at 6:44 AM | marketbeat.comInvesco Ltd. Trims Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 10 at 6:30 AM | marketbeat.comBank of Montreal Can Has $234.04 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 10 at 6:21 AM | marketbeat.comPolymer Capital Management US LLC Takes Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 10 at 6:21 AM | marketbeat.comWe're About to Find Out the Answer to Warren Buffett's Pointed Question About Trump's Tariffs. Here Are 3 Stocks to Buy Depending on What That Answer Is.April 10 at 3:52 AM | fool.comAn Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 41% UndervaluedApril 9 at 7:13 PM | finance.yahoo.comMorgan Stanley Remains a Hold on Vertex Pharmaceuticals (VRTX)April 9 at 7:13 PM | markets.businessinsider.comVertex Pharmaceuticals price target raised to $462 from $459 at Morgan StanleyApril 9 at 7:13 PM | markets.businessinsider.comInvestors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to KnowApril 9 at 10:00 AM | zacks.com5 Top Growth Stocks to Buy in the Stock Market Sell-OffApril 9 at 10:00 AM | fool.com5 Top Growth Stocks to Buy in the Stock Market Sell-OffApril 9 at 10:00 AM | fool.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMXCT, VRTX, and CRSP Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$39.30 +5.04 (+14.71%) Closing price 04/11/2025 04:00 PM EasternExtended Trading$39.11 -0.19 (-0.49%) As of 04/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.MaxCyte NASDAQ:MXCT$2.58 +0.24 (+10.26%) Closing price 04/11/2025 04:00 PM EasternExtended Trading$2.53 -0.05 (-1.94%) As of 04/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.Vertex Pharmaceuticals NASDAQ:VRTX$484.22 +8.73 (+1.84%) Closing price 04/11/2025 04:00 PM EasternExtended Trading$487.11 +2.89 (+0.60%) As of 04/11/2025 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas JPMorgan is a Buy, if You Can Handle The Volatility Rocket Lab Stock: Weathering the Storm, Time for a Comeback? United States Steel's Crash: An Unmissable Buying Opportunity Micron Tumbles on Tariff Threat: Risk/Reward Outlook Improves Is Archer Aviation’s Stock Price Dip a Gift? Marvell Gets Tariff Lifeline But Expect More Volatility Snowflake Boosts Growth by Doubling Down on AI Broadcom's Big Outperformance Shows Strength Amid Tariff Decline Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
